Please assess the completion status of the following clinical trial:

Trial Title: Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age higher than 18;~2. Confirmed diagnosis by osseous biopsy and bone marrow cyto-morphologic counts of blast cells, of Myelodysplastic syndrome without excess of blasts: refractary anemia, refractary anemia with rings sideroblasts, refractary citopenya with multilineage dysplasia,  refractary citopenya with multilineage dysplasia and rings sideroblasts or 5q-syndrome without excess of blasts based on WHO classification (appendix).~3. Low or intermediate-1 IPSS (appendix).~4. Hb \< 11g/dl.~5. rEPO serum level \< 500mU/L.~6. Women in menopause from at least one year.~7. Informed consent~Exclusion Criteria:~1. Myelodisplastic syndrome with excess of blasts (RAEB).~2. IPSS score intermediate-2 or high (appendix).~3. Forecasted allogeneic bone marrow transplant within 1 year after diagnosis(patients younger than 60 years, transfusion dependents or with serious leuko/thrombocytopenia and HLA compatible family donor).Considering the time needed to perform this procedure, the indication of a transplant from non-consanguineous donor has no contraindication to the inclusion in this protocol of the response to rEPO therapy ± differentiating therapy.~4. Renal failure with creatininemia value greater than 3 times the normal limit.~5. Chronic hepatophaty with bilirubinemia value greater than 3 times the normal limit and/or AST or ALT or ALP values greater than 5 times the normal limit.~6. Presence of second tumor or other serious pathology with life expectancy lower than one year.~7. Presence of neurologic or psychiatric pathologies that make the patient unreliable in the acquisition of drugs.~8. Allergy/intolerance known to use drugs.~9. Pregnant women.~10. Women of childbearing age or in menopause from less than one year.~11. Age \< 18 years old.~12. HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infusion A: rEPO (Type: EXPERIMENTAL): rEPO for 4 mounths consequently
- Infusion B combined r-EPO (Type: EXPERIMENTAL): rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently

Based on this trial design, predict the completion outcome and termination type (if applicable).